JP2013515474A5 - - Google Patents

Download PDF

Info

Publication number
JP2013515474A5
JP2013515474A5 JP2012545436A JP2012545436A JP2013515474A5 JP 2013515474 A5 JP2013515474 A5 JP 2013515474A5 JP 2012545436 A JP2012545436 A JP 2012545436A JP 2012545436 A JP2012545436 A JP 2012545436A JP 2013515474 A5 JP2013515474 A5 JP 2013515474A5
Authority
JP
Japan
Prior art keywords
factor
variant
nucleic acid
acid sequence
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP2012545436A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013515474A (ja
Filing date
Publication date
Priority claimed from GBGB0922659.8A external-priority patent/GB0922659D0/en
Application filed filed Critical
Publication of JP2013515474A publication Critical patent/JP2013515474A/ja
Publication of JP2013515474A5 publication Critical patent/JP2013515474A5/ja
Abandoned legal-status Critical Current

Links

JP2012545436A 2009-12-24 2010-12-23 組換え体h因子ならびにそのバリアントおよびコンジュゲート Abandoned JP2013515474A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0922659.8 2009-12-24
GBGB0922659.8A GB0922659D0 (en) 2009-12-24 2009-12-24 Factor H
PCT/GB2010/002334 WO2011077102A1 (en) 2009-12-24 2010-12-23 Recombinant factor h and variants and conjugates thereof

Publications (2)

Publication Number Publication Date
JP2013515474A JP2013515474A (ja) 2013-05-09
JP2013515474A5 true JP2013515474A5 (https=) 2014-02-20

Family

ID=41716988

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012545436A Abandoned JP2013515474A (ja) 2009-12-24 2010-12-23 組換え体h因子ならびにそのバリアントおよびコンジュゲート

Country Status (5)

Country Link
US (3) US8889374B2 (https=)
EP (1) EP2516464B1 (https=)
JP (1) JP2013515474A (https=)
GB (1) GB0922659D0 (https=)
WO (1) WO2011077102A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0922659D0 (en) 2009-12-24 2010-02-10 Univ Edinburgh Factor H
FR2981661B1 (fr) * 2011-10-25 2015-06-19 Lfb Biotechnologies Procede de preparation du facteur h humain
FR3015484A1 (fr) * 2013-12-20 2015-06-26 Lab Francais Du Fractionnement Proteines recombinantes possedant une activite de facteur h
FR3038517B1 (fr) 2015-07-06 2020-02-28 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Utilisation de fragments fc modifies en immunotherapie
CN108291216B (zh) 2015-09-24 2022-09-16 宾夕法尼亚州大学信托人 用于治疗补体介导的疾病的组合物和方法
US10975131B2 (en) * 2015-10-27 2021-04-13 University Of Massachusetts Factor H-Fc immunotheraphy
GB201706808D0 (en) 2017-04-28 2017-06-14 Univ Newcastle Modified complement proteins and uses thereof
GB201800620D0 (en) 2018-01-15 2018-02-28 Univ Manchester C3b Binding Polypeptide
US20210338838A1 (en) * 2018-07-20 2021-11-04 University Of Utah Research Foundation Gene therapy for macular degeneration
JP7222075B2 (ja) * 2018-09-13 2023-02-14 リジェネロン・ファーマシューティカルズ・インコーポレイテッド C3糸球体症のモデルとしての補体因子h遺伝子ノックアウトラット
CA3182800A1 (en) 2020-06-14 2021-12-23 Vertex Pharmaceuticals Inc. Complement factor i-related compositions and methods

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7037504B2 (en) 2001-10-23 2006-05-02 Waratah Pharmaceuticals, Inc. Epidermal growth factor protein and gene, and methods of use therefor
EP1336618A1 (en) 2002-02-15 2003-08-20 HANS-KNÖLL-INSTITUT FÜR NATURSTOFF-FORSCHUNG e.V. Porcine complement regulator factor H and its use
US7745389B2 (en) 2005-02-14 2010-06-29 University Of Iowa Research Foundation Methods for treatment of age-related macular degeneration
US20090118163A1 (en) 2005-09-19 2009-05-07 Peter Gronski Factor H for the Treatment of Chronic Nephropathies and Production thereof
US7759304B2 (en) * 2006-06-21 2010-07-20 Regents Of The University Of Colorado Targeting complement factor H for treatment of diseases
US20110159018A1 (en) 2007-05-03 2011-06-30 Medizinische Universitat Innsbruck Complement factor h-derived short consensus repeat-antibody constructs
WO2008139496A1 (en) 2007-05-16 2008-11-20 Bigtec Private Limited Recombinant human insulin and a method thereof
GB0922659D0 (en) 2009-12-24 2010-02-10 Univ Edinburgh Factor H
US20130011857A1 (en) 2010-02-12 2013-01-10 Cemm Forschungszentrum Fur Molekulare Medizin Gmbh Complement factor h for oxidative stress disease conditions
US9540626B2 (en) 2012-03-19 2017-01-10 The Trustees Of The University Of Pennsylvania Regulator of complement activation and uses thereof

Similar Documents

Publication Publication Date Title
JP2013515474A5 (https=)
NZ598351A (en) Il-17 binding compounds and medical uses thereof
JP2019530463A5 (https=)
JP2012522529A5 (https=)
JP2010534486A5 (https=)
JP2009529856A5 (https=)
NZ602943A (en) Modified binding proteins inhibiting the vegf-a receptor interaction
JP2012525844A5 (https=)
He et al. Identification of SCARA3, SCARA5 and MARCO of class A scavenger receptor-like family in Pseudosciaena crocea
JP2012082206A5 (https=)
MX2012015142A (es) Polipeptidos que tiene actividad beta-glucosidasa y usos del mismo.
NZ603623A (en) Tcr complex immunotherapeutics
JP2011004753A5 (https=)
JP2019506166A5 (https=)
WO2012077950A3 (ko) 히알루론산-단백질 컨쥬게이트 및 이의 제조 방법
IN2012DN03368A (https=)
JP2018537087A5 (https=)
JP2014514921A5 (https=)
WO2013186563A3 (en) Factor viii sequences
EA201300060A1 (ru) Полипептид, обладающий или содействующий активности деградации углеводного материала, и его применение
JP2006149365A5 (https=)
HRP20192080T1 (hr) Terapeutske fuzije nukleaza-albumine i postupci
JP2013530689A5 (https=)
MX2012005864A (es) Proteinas de enlace al antígeno anti-orai 1 y usos de las mismas.
KR20200123132A (ko) 융합 단백질